What You Could Expect at the 5th In Vivo Cell Engineering & Gene Editing Summit
The 5th In Vivo Cell Engineering & Gene Editing Summit was the only congress that brought together the researchers, translational leaders, and strategic decision-makers driving the next stage of in vivo innovation and ex vivo transitions.
Designed for teams navigating real scientific and operational challenges, the meeting offered a focused environment to explore delivery engineering, early clinical signals, CMC scale‑up, and global development pathways with peers facing the same obstacles.
Over three days, attendees had access to detailed case studies, collaborative problem‑solving sessions, and open discussions that delve into practical questions about targeting, off‑tissue activity, manufacturability, and regulatory readiness. With curated networking, working groups, and the new Partnerships Mixer, the summit made it easy to connect with biotechs, pharma, and solution providers advancing programs worldwide.
Whether advancing in vivo programs or exploring how to pivot an established ex vivo platform, this is where developers benchmark strategies, refine their direction, and move forward with clarity.
Event Highlights for 2026
Targeting & Delivery Deep Dives
Attendees gained practical insight into how developers are selecting, optimizing, and comparing delivery vehicles across LNPs, VLPs, LVVs, and emerging nonviral platforms, with real examples of biodistribution, payload performance, and extrahepatic targeting.
Translational Strategies Grounded in Real Data
Explored how developers shaped multinational strategies across the US, Europe, and Asia, including investigator-initiated trial (IIT) design, regulatory touchpoints, site selection, and the operational considerations that influenced speed and cost.
CMC, Scale-Up & Platform Guidance
Experts tackled the operational side of in vivo development, including analytical readiness, comparability expectations, vector and LNP manufacturing, and the practical steps needed to move from early research toward clinical supply.
Global Development Intelligence
Discussions highlighted how developers shaped multinational strategies across the US, Europe, and Asia, including investigator-initiated trial (IIT) design, regulatory touchpoints, site selection, and the operational considerations that influenced speed and cost.
Industry Momentum is Building
Pharma’s surge into in vivo cell engineering and gene editing products has pushed the field to a potential inflection point. With over $7.3B in in vivo acquisitions in the past year, alongside first-in-human signals and rapid modality diversification, momentum is accelerating. Companies are expanding pipelines, speeding up clinical timelines, and competing to develop in vivo platforms that can scale globally.
The field is now expanding beyond traditional indications with more assets targeting solid tumors and autoimmune diseases, enabling access to wider patient and commercial opportunities.
For many organizations, this raises a critical question: when is the right time to define an in vivo strategy? While some teams consider this shift later in development, the pace of innovation and competition means early strategic alignment is becoming essential. Engaging with the latest data, delivery approaches, and peer benchmarks now allows teams to make more informed decisions before key development paths are locked in.
Explore the 2026 Full Program
- 20+ world‑class speakers shaping the future of in vivo
- New “Global Development Spotlight” workshop featuring frontline clinical and manufacturing insights
- In‑depth delivery comparisons across LNP, VLP, LVV, and non‑viral systems
- Exclusive first‑in‑human and translational data presentations
- Dedicated networking, including the Partnerships Mixer and Poster Showcase
Attending Companies Included
Explore the 2026 Full Program
View the detailed agenda, featured speakers, session highlights, and networking opportunities shaping the fastest‑growing frontier in cell and gene therapy.
Secure Your Place
Join the only meeting dedicated to accelerating in vivo cell engineering and gene editing. Connect with global leaders, access exclusive clinical insights for first-in-human trials, and strengthen your development and delivery strategies.
Showcase Your Capabilities
Position your organization in front of senior R&D and CMC decision-makers at the forefront of this growing field. Attendees are seeking CDMOs, CROs, and vector design expertise to scale their in vivo programs.